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Abstract
Objective-To determine fluctuation in
circulating von Willebrand factor (vWF)
in the outcome of patients with temporal
arteritis.
Methods-Plasma vWF antigen concen-
trations were measured in 65 patients with
biopsy proven temporal arteritis at differ-
ent disease activity stages, in 12 with
isolated polymyalgia rheumatica, and in
16 controls. Fourteen temporal arteritis
patients underwent serial determinations
during the course oftheir disease.
Results-vWF concentrations were sig-
nificantly raised in temporal arteritis
(mean 220 [arbitrary units], range 96 to
720) and in polymyalgia rheumatica
(mean 196, range 103 to 266) compared
with healthy controls (mean 98, range 75
to 137) (P < 0.05). Although vWF values
tended to be higher in temporal arteritis,
no significant differences were found
between temporal arteritis and polymyal-
gia rheumatica patients nor between tem-
poral arteritis patients with ischaemic
complications (mean 269, range 130 to
720) and those who presented with
polymyalgia rheumatica or constitutional
symptoms only (mean 179, range 140 to
220). The highest levels were obtained in
patients with associated, mainly infec-
tious, diseases (mean 631, range 240 to
1680). Raised vWF values found in active
temporal arteritis patients (mean 220,
range 96 to 720) persisted within the first
two years after the beginning oftreatment
(mean 244, range 102 to 510) but tended to
normalise in patients in long term remis-
sion (mean 143, range 50 to 260).
Conclusions-Persistent elevation ofvWF
during early remission oftemporal arteri-
tis might represent an endothelial
activation status induced by a remaining
inflammatory microenvironment rather
than a marker ofendothelial cell injury. In
long term remission, decreasing vWF
concentrations might reflect progression
ofinflammatory lesions to a healing stage.
(Ann Rheum Dis 1996;55:927-930)
Over the past years circulating von Willebrand
factor (vWF) has received a great deal of atten-
tion as a potential indicator of endothelial
injury in a variety of diseases.' vWF is a high
molecular weight glycoprotein synthesised by
megakaryocytes and endothelial cells. It circu-
lates in plasma in a multimeric form
non-covalently linked to factor VIII, and inter-
acts with platelet integrins, mediating their
adhesion to the subendothelial matrix of dam-
aged vessels.2
Abnormally high plasma vWF concentra-
tions have been observed in several disorders,
most of which involve blood vessels through
different mechanisms.' 3- Since vWF is stored
in Weibel-Palade bodies of endothelial cells,
the hypothesis has been proposed that
increased vWF concentrations might reflect
the existence of vascular injury."34 Further-
more, several investigators have considered the
measurement of vWF activity potentially
useful for both diagnosis and management of
patients with vasculitis.4
vWF has been especially studied in temporal
arteritis and in its related disorder polymyalgia
rheumatica.' However, doubts about its
usefulness in the day to day management of
these patients have been raised since the
increased concentrations of vWF found in
temporal arteritis remain high in spite of clini-
cal and laboratory determined remission
induced by corticosteroid treatment."'8 Moreo-
ver, during early follow up, vWF fluctuations
have not been useful in predicting flares.8
Whether vWF levels remain indefinitely raised
or eventually return to normal is not known.
In this study we have determined vWF
related antigen (vWFAg) concentrations in a
large series of patients with biopsy proven tem-
poral arteritis in order to analyse their
variations in different activity stages, including
a group of patients with long term follow up.
Methods
The study group consisted of 65 biopsy proven
temporal arteritis patients (20 males and 45
females). Twelve patients (two males and 10
females) fulfilling diagnostic criteria for
polymyalgia rheumatica were also included for
comparison purposes. All of the later had a
negative temporal artery biopsy and never pre-
sented cranial manifestations suggestive of
temporal arteritis during the period of disease
activity or during a three year follow up period.
Data concerning clinical manifestations
were obtained prospectively in patients with
active disease and in those in recent remission.
In individuals in long term remission, clinical
information was obtained from their records
and completed with an interview with every
patient and a general physical examination.
A cross sectional study was performed and
patients were classified according to their
disease activity. Temporal arteritis or
polymyalgia rheumatica were considered active
when patients were clinically symptomatic and
evaluated previously or within the first week
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after starting treatment (prednisone 1 mg kg-'
d-' for temporal arteritis and 15 mg d-' for
polymyalgia rheumatica). They were consid-
ered to be in recent remission when complete
recovery of their symptoms occurred, with
normalisation of erythrocyte sedimentation
rate (ESR), after treatment for at least one
month. Patients were considered to be in long
term remission when they had been
asymptomatic for three or more years after the
beginning of treatment. At the time when
vWFAg was determined four of the latter had
slightly raised or borderline ESR values which
did not result in a clinical flare or require
changes in their treatment schedule.
The control group included 16 healthy
blood donors (nine males, seven females) aged
63 years (range 60-65). The smoking habits of
patients, controls, and pooled plasma donors
were not recorded.
Measurements ofvWFAg were performed as
described.9 A pool of plasma samples from
normal donors was used as a reference and
vWF activity present in this plasma pool was
arbitrarily considered to contain 100 U dl- of
VWFAg activity.
For the cross sectional study, 96 determina-
tions were made: 36 in active temporal arteritis
patients, 24 in temporal arteritis patients in
recent remission (mean seven months, range
one to 20 months), 18 in long term remission
patients (mean six years, range three to 13
years), 12 in patients with active isolated poly-
myalgia rheumatica, and six in patients with
temporal arteritis and associated diseases: one
acute myocardial infarction, four infections
(one pneumonia, one acute pyelonephritis with
sepsis, one miliary tuberculosis, one oropha-
ryngeal candidiasis), and one dehydration and
renal insufficiency secondary to hypercalcae-
mia caused by coincident primary hyperpar-
athyroidism. In addition, 14 active patients
underwent serial determinations at diagnosis
and at one to two months, three to six months,
and one to three years after the beginning of
treatment. None of these patients experienced
significant relapses during their follow up. For
that reason, months/years after the initiation of
treatment are considered equivalent to
months/years in clinical remission.
Simultaneously with vWFAg measurements,
other variables were analysed by routine meth-
ods: ESR (Westergren), haptoglobin (immuno-
precipitation), orosomucoid (immunoprecipi-
tation), C reactive protein (radial immuno-
diffusion), and platelet count and haemoglobin
by usual automated systems.
Analysis of variance (ANOvA) was used for
statistical comparison among different groups
of patients. Bonferroni's method was applied to
correct for multiple comparisons.
Results
Values resulting from vWFAg determinations
are displayed in figs 1 and 2. vWFAg levels in
active temporal arteritis patients (mean 220
arbitrary units, range 96 to 720) were
significantly higher than those obtained from
controls (mean 98, range 75 to 137) (P <
0.05). 'Values obtained from patients with
active isolated polymyalgia rheumatica (mean
196, range 103 to 266) were also significantly
higher than those from normal donors (P <
0.05). Although vWFAg concentrations
tended to be higher in temporal arteritis than
in polymyalgia rheumatica the difference was
not statistically significant (fig 1).
Among patients with active temporal arteri-
tis, 31 had classical cranial symptoms, 1 1 with
ischaemic complications related to temporal
arteritis (seven amaurosis, three amaurosis
fugax, one lower limb ischaemia), and five pre-
sented with polymyalgia rheumatica or consti-
tutional symptoms only. No significant differ-
ences were found in vWF Ag concentrations
between patients with active disease and
ischaemic manifestations (mean 269, range 130
to 720) and those who suffered from polymyalgia
rheumatica or constitutional symptoms only
(mean 179, range 140 to 220). There were also
no differences between the latter group of
temporal arteritis patients and those with isolated
polymyalgia rheumatica. The highest vWF Ag
concentrations were obtained in patients with
temporal arteritis in recent remission suffering
from associated conditions (mean 240, range 240
to 1680)-significantly higher than the values
obtained in patients with active disease or in
those in recent remission but without associated
conditions (P < 0.05).
Twenty two patients with active temporal
arteritis had thrombocytosis (platelet count
greater than 350 x 109 litre-1. No significant dif-
ferences were found in vWF Ag values between
patients with thrombocytosis (mean 229, range
100 to 720) and those without (mean 170,
range 96 to 282). While other variables
(haemoglobin) or acute phase reactants such as
ESR, C reactive protein, haptoglobin, and oro-
somucoid decreased when patients achieved
remission (table), vWFAg remained elevated.
As shown in the table, no significant
differences were found between patients with
active temporal arteritis (mean 220, range 96
to 720) and those in recent remission (mean
244, range 102 to 510). However, vWFAg con-
centrations declined thereafter and were
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Figure 1 Distribution ofplasma vWF antigen
concentrations in 36 patients with active temporal arteritis(T4), 12 patients with polymyalgia rheumatica (PMR),
and 16 control individuals.
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Table 1 vWFAg levels, acute phase rem
artesitis at different clinical activity stages
Active
vWF Ag (U dl-1) 220* (96-720)
ESR (mm/h) 109** (24-105)
Haemoglobin (g dl-') 10.9** (8-14)
Haptoglobin (g dl-') 422** (187-936)
CRP (mgdi-') 5.8t (2.4-9)
Orosomucoid (mg dl-') 169** (83-280)
* P < 0.05 vs long term remission group onl
** P < 0.05 vs both recent remission and lor
t P < 0.05 vs long term remission group onl
VWF Ag, von Willebrand factor related anti
reactive protein.
A were neglected. Consequently, we cannot rule
out the possibility that this variable could have
a slight influence on vWF Ag concentrations in
both patients and controls. Patients with
biopsy proven temporal arteritis tended to have
higher vWF Ag concentrations than were
found in pure, biopsy negative polymyalgia
rheumatica patients but the difference was not
significant. Other investigators67 have found a
------ -------
slight but significant increase in vWF Ag values
in temporal arteritis compared with isolated
polymyalgia rheumatica, and have suggested
I an interesting role for vWF as a marker of vas-
Baseline 1-2 3-6 12-36 cular injury in the evaluation of patients with
apparently isolated polymyalgia rheumatica.
However, in our patients, as well as in other
B reported series,68 vWF Ag concentrations were
highly variable, resulting in a substantial
dispersion among individuals whose clinical
situations were apparently similar. This finding
restricts the potential usefulness of vWF Ag
determinations in evaluating systemic vascular
involvement in individual patients with
suspected vasculitis.
An increase in vWF has been considered to
------ ------ --- ------ -------------- be a result of endothelial injury.' However, this
hypothesis is barely defensible in temporal
arteritis patients. In our series, in agreement
I I with other investigators,56 patients in remission
Baseline 1-2 3-6 12-36 had as high, or even higher, vWF values than
Follow up (months) patients with active disease. It is difficult to
(A) vWF antigen (Ag) concentrations during support the view that patients who have been
zalfoUlow up of 14 patients with temporal arteritis. asymptomatic for several months and in very
dltaneously measured ESR values. Values are
ror bars = SD. Dashed line illustrates reference good health have extensive endothelial inury.
>ooled plasma from normal individuals (vWF In fact, we found no significant differences
upper normal level (ESR). between temporal arteritis patients with severe
ischaemic complications, in whom more severe
antly lower in patients in long term
an (mean 143, range 50 to 260) than in vascular damage is likely, and those whopresented with polymyalgia rheumatica or con-
stitutional symptoms only. In addition, raised05) and were similar to those obtained
&controlg oup. vWF concentrations have been reported ine control geroup determinationsp conditions in which a direct vascularit fropatientserithtemporalnatns at involvement is not a distictive feature'0 and,indeed, in our patients, the highest vWF Ag
'is and during follow up are shown in fig concentrations were obtained in those with
~eping with the data obtained from thenaobanentraon associated, mainly infectious, diseases. From a
-ctional study, VWF Ag concentrations ..clinical point of view, these observations
.d raised during the first three years of emphasise the lack of specificity of increasedip. vWFAg values and suggest that a very high
vWF Ag in the initial follow up of temporalglOplasma concentrations were raised in arteritis might indicate the coexistence of an
gesofplasma entrtoswittemorel aratised associate disease rather than a relapse of thejes of patients with temporal rt ritis,tmoaareisprs.
n those with current disease activity or vWF areleaseben
it remission. In our study, as well as in . vWF Ag release by endothelial cells can be
previously published series.,' the mduced by proinflammatory cytokines in
.'totpu nu vitro." It is likely that a persistence of raised
vWF concentrations in temporal arteritis
ctants, and other activity markers in temporal patients in remission represents continuing low
Values are means (range) level inflammatory activity in the vessel wall
and local endothelial cell activation by
Recent remissiwn Longterm remission cytokines in the vascular microenvironment.
244* (102-510) 143 (50-260) Although clinical manifestations and some
28 (1-66) 24 (2-57) lymphocyte activation markers in lesions are
14.3 (12-16) 13.8 (11-15) . . .
sa176 (44-314) 167 (69-237) quickly respoive tO steroid treatment, the
3.6 (2-5.2) 0.9 (0.7-1) mechanisms that retain inflammatory cells in
88 (66-128) 75 (49-111) the vessel wall do not respond so clearly. Arter-
Iy. itic lesions have been shown to persist for
ng term remission groups. months and even years in some clinically
Ly.
gen; ESR, erythrocyte sedimentation rate; CRP,C asymptomatic patients with temporal arteri-tis."3 Furthermore, neovascularisation within
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the inflammatory infiltrates is a prominent but
underestimated phenomenon in temporal
arteritis lesions814 and vWF Ag production
increases during endothelial cell proliferation.'5
Therefore, it is possible that raised vWF
concentrations could also be a result of active
neovascularisation and vessel repair.
Interestingly, vWF Ag concentrations in
patients in long term remission decreased
significantly and tended to normalise. A vWF
Ag decrease in temporal arteritis patients in
long term remission could reflect the outcome
of arteritic lesions since over the years the
number of patients who reach the healing
histological pattern seems to increase."
In summary, our data suggest that vWF Ag
concentrations are not useful in the day to day
management of patients with temporal arteritis
in recent remission, nor in distinguishing
between temporal arteritis and polymyalgia
rheumatica. However, a decrease in vWF Ag
levels can be observed in patients in long
lasting remission. Prospective studies must be
carried out to discover whether vWF Ag deter-
mination in patients in long term remission
could be useful in decisions about the
withdrawal of corticosteroid treatment.
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